drugset / Trial / NCT05679258
A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity (Randomized, Double-blind, Parallel Controlled) of HLX15 with Daratumumab Injection in Healthy Chinese Male Subjects
Timeline
- Start
- 2023-01-31
- Primary completion
- 2024-03-16
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Daratumumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | HLX15 | Monoclonal antibody | 8 mg/kg | Intravenous |